Homology Medicines, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Homology Medicines, Inc.
Many gene therapies companies have faced R&D and financial problems this year but the longer term potential of the field and low prices might tempt big pharma into deals.
Restructuring Updates: Homology implemented modest job cuts as it ended a gene therapy trial, while ProQR revealed its second round of layoffs this year and Synthetic Biologics shifted focus to oncolytic virus pipeline. Also, Bolt, MacroGenics and others deprioritized programs in their Q2 updates.
BMN 307 for phenylketonuria was put on a clinical hold in September due to liver cancer observed in mice and was expected to lift in Q1 of 2022, but the US FDA has requested additional preclinical studies.
Sio Gene Therapies’ Exit From Oxford Biomedica Parkinson’s Collaboration Leaves Hole In Commercial Prospects
Sio Gene Therapies is returning its rights for a Parkinson’s disease program to Oxford Biomedica, leaving observers regretting the loss of a big market opportunity, while the US firms seeks a new CEO.
- Gene Therapy, Cell Therapy